Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00801372|
Recruitment Status : Recruiting
First Posted : December 3, 2008
Last Update Posted : November 28, 2017
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.
The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.
|Condition or disease|
|Pregnant, Healthy Females Healthy Male Newborns|
The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.
The clinical grade donated feeders used in this project were developed under GMP conditions using animal-free reagents. For potential future clinical applications, the iPS cells will be developed under GMP conditions, using reagents and methods that will be acceptable for clinical applications.
|Study Type :||Observational|
|Estimated Enrollment :||1 participants|
|Official Title:||Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells|
|Study Start Date :||November 2008|
|Estimated Primary Completion Date :||December 2025|
|Estimated Study Completion Date :||December 2025|
Pre-existing Fibroblast MCB
Pre-existing fibroblast donors for hESC derivation project
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801372
|Contact: Benjamin E Reubinoff, PhD MDfirstname.lastname@example.org|
|Contact: Shelly E. Tannenbaum, MSQAemail@example.com|
|Hadassah Ein Kerem||Recruiting|
|Jerusalem, Israel, 9112100|
|Contact: Benjamin E Reubinoff, Professor 972-2-6776424/5 firstname.lastname@example.org|
|Contact: Shelly E Tannenbaum, MSQA 972-2-6775700 email@example.com|